Hanmi Pharm is developing the salt alteration product of Tamifly to avoid the patent
Hanmi Pharm has begun to develop the salt alteration product of the flu treatment, Tamiflu.
This is because it is trying to avoid the Roche’s salt patent for Tamiflu; the decisions between Hanmi Pharm and other domestic pharmaceutical companies that have applied generic approvals are expected to...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
